Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLSEEK-1: Golcadomide plus R-CHOP vs placebo plus R-CHOP in previously untreated high-risk large B-cell lymphoma
jRCT2031240194Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) comparing Golcadomide plus R-CHOP with Placebo plus R-CHOP (2 arms). Primary endpoint: Progression-Free Survival (PFS). Started Jul 2024; status: active, not recruiting.
02
Drugs
golcadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaT-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)
Beyond the preview
Go deeper on jRCT2031240194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240194.